ESR1 and cancer: In treatment of pre-menopausal women with advanced BCa, the response rates ranged from 20% to 45%, while for ERα+ and ERα+/PR + cancers response rates were 50% and 60–70%, respectively, for post-menopausal women with advanced BCa [143].